Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases

26Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Interleukin (IL)-17-producing T cells, especially T helper (Th)17 cells, play a critical role in the pathogenesis of a variety of autoimmune inflammatory diseases. The pathogenic function of Th17 cells results from their production of Th17 effector cytokines, namely IL-17 (or IL-17A), IL-17F, IL-22 and IL-26. The importance of IL-17 has been demonstrated by antibody neutralization studies in both animal models of autoimmune diseases as well as in human clinical trials. This review highlights the current knowledge of the clinical aspects of the Th17 cytokines as well as therapeutic antibodies against IL-17, IL-17F, IL-17 receptor, IL-22, IL-26 and granulocyte macrophage colony-stimulating factor for the future treatment of autoimmune inflammatory diseases.

Cite

CITATION STYLE

APA

Yamagata, T., Skepner, J., & Yang, J. (2015, December 1). Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases. Archivum Immunologiae et Therapiae Experimentalis. Birkhauser Verlag AG. https://doi.org/10.1007/s00005-015-0362-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free